We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Colon Cancer Cells Adopt Stem Cell Characteristics to Metastasize to the Liver

By LabMedica International staff writers
Posted on 12 Jul 2015
Print article
Image: Normal human colonic crypts are pictured. SMOC-2 expression (red) in the colonic stem cells demonstrates that these cells are localized in the bottoms of the crypts. Bars represent 100 micrometers (left) and 50 micrometers (right) (Photo courtesy of the Weizmann Institute of Science).
Image: Normal human colonic crypts are pictured. SMOC-2 expression (red) in the colonic stem cells demonstrates that these cells are localized in the bottoms of the crypts. Bars represent 100 micrometers (left) and 50 micrometers (right) (Photo courtesy of the Weizmann Institute of Science).
Cancer researchers have identified an interlocked set of enzyme activities, similar to those found in stem cells, expressed in colorectal cancer (CRC) cells, which confer on these cells the enhanced cellular motility required for metastasis into the liver.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) worked with mouse models of colorectal cancer metastasis to the liver. The first gene they linked to metastasis was L1. L1 family members are able to bind to a number of other proteins. As cell adhesion molecules, they often bind "homophilically" to themselves; for example L1 on one cell binding to L1 on an adjacent cell. L1 family members also bind "heterophilically" to members of the contactin or CNTN1 family. In addition, L1 family members bind to many cytoplasmic proteins such as ezrin-moesin-radixin (ERM) proteins and to various signaling molecules and proteins important in trafficking.

The investigators reported in the April 27, 2015, online edition of the journal Oncogene that L1 could confer enhanced motility and liver metastasis when expressed in CRC cells. This ability of L1-mediated metastasis was exerted by a mechanism involving ezrin and the activation of NF-kappaB target genes. Ezrin is a cytoplasmic peripheral membrane protein that functions as a protein-tyrosine kinase substrate in microvilli. As a member of the ERM protein family, ezrin serves as an intermediate between the plasma membrane and the actin cytoskeleton. It plays a key role in cell surface structure adhesion, migration, and organization and has been implicated in various human cancers.

In the present study, the investigators identified SMOC-2 (secreted modular calcium-binding matricellular protein-2) as a gene activated by L1-ezrin-NF-kappaB signaling. The induction of SMOC-2 expression in L1-expressing CRC cells was necessary for the increase in cell motility, proliferation under stress, and liver metastasis conferred by L1. SMOC-2 was localized at the bottom of normal human colonic crypts and at increased levels in CRC tissue with preferential expression in invasive areas of the tumor.

"This research," said senior author Dr. Avri Ben-Ze'ev, professor of genetics at the Weizmann Institute of Science, "provides support for the idea that as cancer develops, it also reverts—that is, some of its cells adopt a less mature, more stem-like, state that assists metastasis. Additional investigations into the interactions between SMOC-2 and other genes suggested that the human cancer cells were, indeed, taking on some qualities of stem cells. We hope that further research will point to ways of interfering with the activities of genes like SMOC-2, thus preventing this cancer from metastasizing. In addition, the expression patterns of SMOC-2 could make it an ideal marker for the early detection of human metastatic colorectal cancer."

Related Links:

Weizmann Institute of Science


Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Hepatitis B Virus Test
HBs Ab – ELISA
New
FLU/RSV Test
Humasis FLU/RSV Combo

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.